arrow
E

Erika Bonacina

vall d’hebron institut de recerca
H指数:11
被引数:377

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prediction of preterm pre-eclampsia and preterm small-for-gestational-age at 24–28 weeks of gestation using ultrasound and biochemical markers in high-risk pregnancies treated with aspirin: A secondary analysis of the StopPRE trial

使用超声和生物化学标志物预测接受阿司匹林治疗的高危妊娠在24~28周时的早产子痫前期和早产胎儿宫内生长受限:StopPRE试验的二次分析

2026-09-300
PRE
Angiogenic factors and fetal Doppler for predicting adverse pregnancy outcome in early-onset small fetuses with and without pre-eclampsia

血管生成因子和胎儿多普勒在预测伴有或不伴有子痫前期早期发病的小胎儿不良妊娠结局中的应用

2026-02-220
OAAI
Aspirin Discontinuation at 24-28 Weeks and Placental Biomarker Trajectories: Post Hoc Analysis of a Randomised Trial

阿司匹林在24-28周停药与胎盘生物标志物轨迹:一项随机试验的事后分析

2025-09-010
PRE
Role of routine uterine artery Doppler at 18-22 and 24-28 weeks' gestation following routine first-trimester screening for pre-eclampsia

常规妊娠早期筛查先兆子痫后,在妊娠18-22和24-28周时常规子宫动脉多普勒的作用

2024-12-050
PRE
Placental growth factor at 24-28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of StopPRE trial
2024-08-222
OAAI
Clinical effectiveness of routine first-trimester combined screening for pre-eclampsia in Spain with the addition of placental growth factor
2023-10-092
OA
Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial Comment
2023-08-010
PRE
Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia A Randomized Clinical Trial
2023-02-2124
OA
Shared risk factors for COVID-19 and preeclampsia in the first trimester: An observational study

妊娠早期新型冠状病毒肺炎和先兆子痫的共同危险因素: 一项观察性研究

2022-05-034
OAAI
Soluble fms-like tyrosine kinase to placental growth factor ratio in different stages of early-onset fetal growth restriction and small for gestational age

早发型胎儿生长受限和小于胎龄儿不同阶段可溶性fms样酪氨酸激酶与胎盘生长因子比值

2020-09-1431
OAAI